We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
In the latest trading session, Organon (OGN - Free Report) closed at $8.61, marking a +2.14% move from the previous day. The stock exceeded the S&P 500, which registered a loss of 0.53% for the day. Elsewhere, the Dow saw a downswing of 0.09%, while the tech-heavy Nasdaq depreciated by 1%.
The pharmaceutical company's stock has climbed by 20.95% in the past month, exceeding the Medical sector's gain of 0.09% and the S&P 500's gain of 2.06%.
Analysts and investors alike will be keeping a close eye on the performance of Organon in its upcoming earnings disclosure. The company is forecasted to report an EPS of $0.74, showcasing a 17.78% downward movement from the corresponding quarter of the prior year. Our most recent consensus estimate is calling for quarterly revenue of $1.53 billion, down 3.84% from the year-ago period.
OGN's full-year Zacks Consensus Estimates are calling for earnings of $3.78 per share and revenue of $6.24 billion. These results would represent year-over-year changes of -8.03% and 0%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Organon. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Organon currently has a Zacks Rank of #3 (Hold).
Investors should also note Organon's current valuation metrics, including its Forward P/E ratio of 2.15. This expresses a discount compared to the average Forward P/E of 15.3 of its industry.
Meanwhile, OGN's PEG ratio is currently 1.66. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Medical Services stocks are, on average, holding a PEG ratio of 1.91 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 194, which puts it in the bottom 21% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow OGN in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know
In the latest trading session, Organon (OGN - Free Report) closed at $8.61, marking a +2.14% move from the previous day. The stock exceeded the S&P 500, which registered a loss of 0.53% for the day. Elsewhere, the Dow saw a downswing of 0.09%, while the tech-heavy Nasdaq depreciated by 1%.
The pharmaceutical company's stock has climbed by 20.95% in the past month, exceeding the Medical sector's gain of 0.09% and the S&P 500's gain of 2.06%.
Analysts and investors alike will be keeping a close eye on the performance of Organon in its upcoming earnings disclosure. The company is forecasted to report an EPS of $0.74, showcasing a 17.78% downward movement from the corresponding quarter of the prior year. Our most recent consensus estimate is calling for quarterly revenue of $1.53 billion, down 3.84% from the year-ago period.
OGN's full-year Zacks Consensus Estimates are calling for earnings of $3.78 per share and revenue of $6.24 billion. These results would represent year-over-year changes of -8.03% and 0%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Organon. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Organon currently has a Zacks Rank of #3 (Hold).
Investors should also note Organon's current valuation metrics, including its Forward P/E ratio of 2.15. This expresses a discount compared to the average Forward P/E of 15.3 of its industry.
Meanwhile, OGN's PEG ratio is currently 1.66. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Medical Services stocks are, on average, holding a PEG ratio of 1.91 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 194, which puts it in the bottom 21% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow OGN in the coming trading sessions, be sure to utilize Zacks.com.